XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 25.65

+2.6%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Chris Boylan who wrote (9019)	3/9/1999 10:52:00 AM
From: aknahow	Read Replies (2) of 17367

Since the trial was not stopped earlier or now because of futility, we know Neuprex is producing a favorable result. We do not know if this result is statistically significant. We do know that anything that reduces the number of deaths, also makes reaching the pre established number of deaths more difficult. For me, the logic is compelling. Neuprex, "works". How well? I don't know. I am thinking of a number between 35 and 45. I am also thinking, what purpose is still served by not revealing the "target" at this point? Wonder if the DSMB was even asked if the target can now be revealed? I would respect a logical reason for not revealing the target. And in fact have defended the concealment of such a target early on in the trials. Would appreciate any ideas on why concealment still has a valid purpose with 370 patients accrued.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next